Direkt zum Inhalt
Merck

Varicella Viruses Inhibit Interferon-Stimulated JAK-STAT Signaling through Multiple Mechanisms.

PLoS pathogens (2015-05-15)
Marieke C Verweij, Mary Wellish, Travis Whitmer, Daniel Malouli, Martin Lapel, Stipan Jonjić, Juergen G Haas, Victor R DeFilippis, Ravi Mahalingam, Klaus Früh
ZUSAMMENFASSUNG

Varicella zoster virus (VZV) causes chickenpox in humans and, subsequently, establishes latency in the sensory ganglia from where it reactivates to cause herpes zoster. Infection of rhesus macaques with simian varicella virus (SVV) recapitulates VZV pathogenesis in humans thus representing a suitable animal model for VZV infection. While the type I interferon (IFN) response has been shown to affect VZV replication, the virus employs counter mechanisms to prevent the induction of anti-viral IFN stimulated genes (ISG). Here, we demonstrate that SVV inhibits type I IFN-activated signal transduction via the JAK-STAT pathway. SVV-infected rhesus fibroblasts were refractory to IFN stimulation displaying reduced protein levels of IRF9 and lacking STAT2 phosphorylation. Since previous work implicated involvement of the VZV immediate early gene product ORF63 in preventing ISG-induction we studied the role of SVV ORF63 in generating resistance to IFN treatment. Interestingly, SVV ORF63 did not affect STAT2 phosphorylation but caused IRF9 degradation in a proteasome-dependent manner, suggesting that SVV employs multiple mechanisms to counteract the effect of IFN. Control of SVV ORF63 protein levels via fusion to a dihydrofolate reductase (DHFR)-degradation domain additionally confirmed its requirement for viral replication. Our results also show a prominent reduction of IRF9 and inhibition of STAT2 phosphorylation in VZV-infected cells. In addition, cells expressing VZV ORF63 blocked IFN-stimulation and displayed reduced levels of the IRF9 protein. Taken together, our data suggest that varicella ORF63 prevents ISG-induction both directly via IRF9 degradation and indirectly via transcriptional control of viral proteins that interfere with STAT2 phosphorylation. SVV and VZV thus encode multiple viral gene products that tightly control IFN-induced anti-viral responses.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Saccharose, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
Saccharose, ≥99.5% (GC)
Sigma-Aldrich
Formaldehyd -Lösung, for molecular biology, 36.5-38% in H2O
Sigma-Aldrich
Saccharose, ≥99.5% (GC), BioXtra
Sigma-Aldrich
Saccharose, BioUltra, for molecular biology, ≥99.5% (HPLC)
Sigma-Aldrich
Ethylendiamintetraessigsäure -Lösung, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Formaldehyd -Lösung, ACS reagent, 37 wt. % in H2O, contains 10-15% Methanol as stabilizer (to prevent polymerization)
Sigma-Aldrich
Saccharose, ≥99.5% (GC), BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Formaldehyd -Lösung, for molecular biology, BioReagent, ≥36.0% in H2O (T)
Sigma-Aldrich
Saccharose, ≥99.5% (GC)
Sigma-Aldrich
Trimethoprim, ≥98.5%
Sigma-Aldrich
Ethylendiamintetraessigsäure, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
Ethylendiamintetraessigsäure, anhydrous, crystalline, BioReagent, suitable for cell culture
Sigma-Aldrich
Ethylendiamintetraessigsäure, 99.995% trace metals basis
Sigma-Aldrich
Saccharose, ≥99.5% (GC), Grade II, suitable for plant cell culture
Sigma-Aldrich
Trimethoprim, ≥99.0% (HPLC)
Sigma-Aldrich
Saccharose, Grade I, ≥99% (GC), suitable for plant cell culture
Sigma-Aldrich
Ethylendiamintetraessigsäure, anhydrous, BioUltra, ≥99% (titration)
Sigma-Aldrich
Formaldehyd -Lösung, meets analytical specification of USP, ≥34.5 wt. %
Sigma-Aldrich
Saccharose, ACS reagent
Sigma-Aldrich
Saccharose, puriss., meets analytical specification of Ph. Eur., BP, NF
Sigma-Aldrich
Z-Leu-Leu-Leu-al, ≥90% (HPLC)
Sigma-Aldrich
Ethylendiamintetraessigsäure, purified grade, ≥98.5%, powder
Sigma-Aldrich
Saccharose, meets USP testing specifications
Sigma-Aldrich
Formaldehyd-12C -Lösung, 20% in H2O, 99.9 atom % 12C
Sigma-Aldrich
MISSION® esiRNA, targeting human IRF9, RP11-468E2.4